Special drug-use survey of Tarlige tablet (evaluation of safety in patients with impaired renal function)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224834

Enrollment

1800

Registered

2019-08-20

Start date

2019-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral neuropathic pain

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with peripheral neuropathic pain not treated with Tarlige tablet before 2.Patients with creatinine clearance (using the Cockcroft-Gault equation, pre-dialysis values for dialysis patients) within 12 months before starting administration of Tarlige tablet, and for whom the degree of impaired renal function can be confirmed 3.Patients who started administration of Tarlige tablet during the contract period (contract period based on the contract with each medical site) 4.Patients who started administration of Tarlige tablet during the registration period 5.Patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients who do not meet eligibility criteria

Design outcomes

Primary

Measure	Time frame
safety Incidence of adverse drug reaction with dizziness Incidence of adverse drug reaction with somnolence	—

Secondary

Measure	Time frame
safety Incidence of adverse drug reaction leading to treatment discontinuation	—

Countries

Japan

Contacts

Public ContactGPSP Contact

GPSP for Contact

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026